Change to the Roche Corporate Executive Committee
15 January 2013 | By Roche
John C. Reed, M.D., Ph.D., has been appointed Head of Roche pRED and member of the enlarged Corporate Executive Committee...
List view / Grid view
15 January 2013 | By Roche
John C. Reed, M.D., Ph.D., has been appointed Head of Roche pRED and member of the enlarged Corporate Executive Committee...
22 December 2012 | By Roche
First medicine approved to treat influenza in infants two weeks of age and older...
18 December 2012 | By Roche
Roche announced the global launch (excluding US) of cobas b 101...
14 December 2012 | By Roche
Positive opinion for the use of Perjeta (pertuzumab)...
12 December 2012 | By Roche
Roche announced plans to invest over 240 million Swiss francs in its Penzberg biotechnology centre...
8 December 2012 | By Roche
Roche announced results from two studies...
8 December 2012 | By Roche
Roche announced updated survival results from the Phase III CLEOPATRA study...
5 December 2012 | By Roche
Roche and the IMI launch StemBANCC...
17 November 2012 | By Roche
Results from positive phase III AVAglio study...
16 November 2012 | By Roche
The continued use of Avastin based therapy beyond first progression in metastatic colorectal cancer patients leads to survival benefits...
31 October 2012 | By Roche
The EC has approved Avastin...
In this qPCR In-Depth Focus: Setting the bar; Q & A - Mikael Kubista from the TATAA Biocenter poses five questions for Jay Brock, Senior Manager, Applications and Technical Support, USB® Life Science Reagents from Affymetrix; Not your grandfathers’ real-time PCR...
16 October 2012 | By Roche
Hospital point-of-care system for blood glucose testing with improved accuracy and wireless data transfer Next-generation system...
1 October 2012 | By Roche
Updated survival results from the Phase III EMILIA study...
1 October 2012 | By Roche
Final results from the Phase III HERA trial...